| CAS NO: | 1204219-80-6 |
| 包装 | 价格(元) |
| 500 μg | 电议 |
| 1mg | 电议 |
| Cas No. | 1204219-80-6 |
| 别名 | 达格列净-D5,BMS-512148-d5 |
| Canonical SMILES | ClC(C=CC([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)=C2)=C2CC3=CC=C(OC([2H])([2H])C([2H])([2H])[2H])C=C3 |
| 分子式 | C21H20ClD5O6 |
| 分子量 | 413.9 |
| 溶解度 | DMF: 30 mg/ml,DMSO: 30 mg/ml,Ethanol: 30 mg/ml |
| 储存条件 | Store at 4°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | Dapagliflozin-d5is intended for use as an internal standard for the quantification of dapagliflozin by GC- or LC-MS. Dapagliflozin is a first generation, selective sodium-glucose linked transporter (SGLT) inhibitor that blocks glucose transport with about 100-fold selectivity for SGLT2 (Ki= 6 nM; EC50= 1.1 nM) over SGLT1 (Ki= 390 nM).1After single oral doses ranging from 0.1 to 1.0 mg/kg, dapagliflozin increases urinary glucose excretion in both normal and diabetic rats, improves glucose tolerance in normal rats, and reduces hyperglycemia in Zucker diabetic fatty rats.2Within two weeks of treating diabetic rats with 0.1 to 1.0 mg/kg dapagliflozin, fasting and fed glucose levels have been shown to be significantly lowered as a result of increased glucose utilization accompanied by reduced glucose production. 1.Chao, E.C., and Henry, R.R.SGLT2 inhibition - A novel strategy for diabetes treatmentNature Reviews.Drug Discovery9(7)551-559(2010) 2.Han, S., Hagan, D.L., Taylor, J.R., et al.Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic ratsDiabetes57(6)1723-1729(2008) |
m.cnreagent.com